Clinical trials · Connecticut
Type 1 diabetes clinical trials in Connecticut
We’re tracking 28 recruiting type 1 diabetes studies with a site in Connecticut — including Early Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Connecticut
- NCT07224321RecruitingPhase 2
Inhaled insulin for youth with newly diagnosed type 1 diabetes
This study tests an inhaled insulin called Afrezza for teenagers and children who have just been diagnosed with type 1 diabetes. It aims to see if this new way of taking insulin can help manage blood sugar and fit into their lives.
New Haven, ConnecticutAges 6–17 - NCT07228117Recruiting
Testing a new automated insulin pump for people with diabetes
This study tests a new automated insulin delivery system (a pump that helps manage blood sugar) in children and adults with diabetes. It aims to see if the system is safe and easy to use in daily life.
New Haven, ConnecticutAges 7–85 - NCT07088068RecruitingPhase 3
Teplizumab for newly diagnosed type 1 diabetes
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
New Haven, ConnecticutAges 1–25 - NCT05762107RecruitingPhase 2
Drug ZT-01 to reduce low blood sugar at night
This Phase 2 study tests ZT-01 to help prevent night-time low blood sugar (hypoglycemia) in people with type 1 diabetes. It may help if you’ve had low blood sugar during sleep or are at high risk based on recent glucose monitoring.
New Haven, ConnecticutAges 18–75 - NCT07579702Recruiting
Omnipod 6 Versus Omnipod 5 Insulin Pump System
This study compares two versions of the Omnipod insulin pump system to see if the newer Omnipod 6 works better at managing blood sugar than the current Omnipod 5. You'll wear one of these systems for several months and share data about how well it helps control your diabetes.
New Haven, ConnecticutAges 14–75 - NCT06967701Recruiting
Building exercise habits for type 1 diabetes
This study helps adults with type 1 diabetes who don't exercise much build a safe and lasting exercise routine. You'll learn how to start moving more while managing your insulin and blood sugar levels.
New Haven, ConnecticutAges 30–65 - NCT07662213RecruitingPhase 3
Elecoglipron vs semaglutide for type 2 diabetes
This study tests an experimental diabetes pill (elecoglipron) to see if it works as well as a current medicine, semaglutide, for people with type 2 diabetes who also have heart risk factors. It aims to help better control blood sugar and weight.
Bridgeport, ConnecticutAges 18 years+ - NCT05286892Recruiting
Diabetes education for people returning home from prison
This study offers diabetes learning through virtual (online) sessions for adults with diabetes who are transitioning back to community living after prison. It aims to help you better manage diabetes during reentry and improve day-to-day health.
Storrs Mansfield, ConnecticutAges 18 years+ - NCT05317455RecruitingEarly Phase 1
Studying brain sugar changes in adults with risky low blood sugar
This early-stage study looks at how the brain uses sugar in people with type 1 diabetes who have had severe or hard-to-notice low blood sugar. It may help researchers understand the brain effects of low blood sugar and guide safer care.
New Haven, ConnecticutAges 18–55 - NCT06481904Recruiting
Registry for stage 2 type 1 diabetes
This study tracks people with stage 2 type 1 diabetes to see how they do over time, either with or without treatment with a drug called TZIELD. It helps doctors learn more about the disease and the effects of this treatment.
New Haven, ConnecticutAges Any age - NCT07059806Recruiting
T1CARE: Help for young adults with type 1 diabetes
This trial tests a new program to help young adults with type 1 diabetes manage social factors that affect their health, like housing or food access. It aims to improve diabetes care by addressing these everyday challenges.
New Haven, ConnecticutAges 18–40 - NCT07061574RecruitingPhase 1/Phase 2
Low-dose ATG with Adalimumab or Verapamil for new type 1 diabetes
This study tests if giving a low dose of an immune-suppressing drug (ATG) followed by either adalimumab or verapamil can help preserve insulin production in people recently diagnosed with type 1 diabetes. You may qualify if you are 9 to 20 years old, have had type 1 diabetes for less than 6 months, and have some natural insulin left.
New Haven, ConnecticutAges 9–20 - NCT07062887Recruiting
Digital mindfulness for young adults with type 1 diabetes
This study tests a digital mindfulness program designed to help young adults manage the stress of living with type 1 diabetes. If you are between 18 and 30, use a continuous glucose monitor, and have a smartphone, you may be able to join.
New Haven, ConnecticutAges 18–30 - NCT07155252Recruiting
Home glucose test for type 1 diabetes screening
This study looks at whether you can do an oral glucose tolerance test at home instead of at a clinic. It is for people who have certain antibodies linked to type 1 diabetes or who were recently diagnosed with type 1 diabetes.
New Haven, ConnecticutAges 8–45 - NCT02734277Recruiting
Extending a past Type 1 diabetes immune study
This study is for people who already took part in an earlier immune-tolerance program for Type 1 diabetes. It tests whether continuing follow-up and assessments can be done safely and may help learn more about long-term immune effects of treatment.
New Haven, ConnecticutAges 8–35 - NCT06411210RecruitingPhase 2
Weight loss medication for young adults with type 1 diabetes
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
New Haven, ConnecticutAges 18–30 - NCT07662044RecruitingPhase 3
Studying elecoglipron for type 2 diabetes
This trial tests a new medicine called elecoglipron, taken alone or with another diabetes drug (dapagliflozin), to see if it helps control blood sugar better than a placebo. It may be an option if your current treatment isn't working well enough.
Bridgeport, ConnecticutAges 18 years+ - NCT04334707Recruiting
Study kidney damage in people with long-term diabetes
This study is looking at different kidney health patterns in people with diabetes, especially diabetic kidney disease and people who have not developed kidney damage despite long-term diabetes. It may help researchers understand why kidney problems happen—and what protective factors might prevent them.
New Haven, ConnecticutAges 18 years+ - NCT06171412Recruiting
Peer mentoring to help Black and Latinx people with type 1 diabetes use CGM more
This study tests whether support from a peer mentor can help Black and Latinx adults with type 1 diabetes who currently use a continuous glucose monitor (CGM) less than half the time to use it more regularly. You'll join remote video sessions with a mentor who has experience with diabetes.
New Haven, ConnecticutAges 13–21 - NCT06487962Enrolling by invitation
Study on continuous glucose monitors for low-income adults with type 1 diabetes
This trial tests a program to help low-income adults with type 1 diabetes use continuous glucose monitors (CGM). You and a family member or friend will attend four weekly sessions to learn how to get the most out of the device.
Middletown, ConnecticutAges 18 years+ - NCT00097292Recruiting
Preventing Type 1 Diabetes in At-Risk People
This study looks for people at high risk of developing type 1 diabetes (based on family history or blood markers) and follows them over time to understand disease development. The goal is to eventually prevent or delay type 1 diabetes in people who don't have it yet.
New Haven, ConnecticutAges 2–45 - NCT06739122RecruitingPhase 3
A study of dulaglutide for children with type 2 diabetes
This trial tests if a weekly injection of dulaglutide (Trulicity) can help children with type 2 diabetes control their blood sugar when used together with metformin and/or insulin. It may be an option for kids who are overweight.
New Haven, ConnecticutAges 10–17 - NCT07064473RecruitingPhase 3
Testing vicadrostat plus empagliflozin for diabetes, high blood pressure, and heart disease
This study tests a new pill called vicadrostat taken with another medicine (empagliflozin) to see if it helps people with type 2 diabetes, high blood pressure, and heart disease. It may reduce the risk of heart problems, but you must not have had heart failure or use certain other heart medications.
Bridgeport, ConnecticutAges 18 years+ - NCT07654374RecruitingPhase 3
Study of a new pill for weight loss and diabetes
This study tests a new daily pill (aleniglipron) to help adults with excess weight and type 2 diabetes lose weight and improve blood sugar control. It may be a good fit if you have a BMI of 27 or higher and your diabetes is managed with A1c between 6.5% and 10%.
Waterbury, ConnecticutAges 18–79
Type 1 diabetes trials by city in Connecticut
Where these studies are running in Connecticut
Institutions with a site for the recruiting type 1 diabetes studies listed above.
- Yale University · 5 studies
- Yale School of Medicine · 4 studies
- Research Site · 3 studies
- Yale Pediatric Diabetes Center · 3 studies
- Yale University School of Medicine · 2 studies
- Cardiology Associates of Fairfield County
- CMR of Greater New Haven
- Community Health Center, Inc.
What taking part in a type 1 diabetes study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Type 1 diabetes trials in other states
Common questions
- Are there type 1 diabetes clinical trials in Connecticut?
- Yes. We're currently tracking 28 recruiting type 1 diabetes studies with a site in Connecticut, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a type 1 diabetes study in Connecticut?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Connecticut to take part?
- Not necessarily. These studies have a site in Connecticut, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a type 1 diabetes trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New type 1 diabetes studies open in Connecticut regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.